Home

#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk

2021/11/29

The Peter Attia Drive

Frequently requested episodes will be transcribed first

Chapters

Shownotes Transcript

No transcript made for this episode yet, you may request it for free.

#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk

The Peter Attia Drive

Chapters

Why is the current 10-year risk assessment of CVD problematic for prevention?

What are the basics of cholesterol, apoB, and plasma lipoproteins?

How does particle cholesterol concentration impact CVD compared to the number of particles?

What are the limitations of standard blood panels in assessing CVD risk?

Remnant type III hyperlipoproteinemia—high cholesterol, low Apo B, high triglyceride

Can apoB effectively estimate the risk of CVD?

How is Mendelian randomization supporting ApoB as a superior risk metric?

What role does hypertension play in CVD risk?

What factors influence the decision to start preventative intervention for CVD?

How effective is the coronary artery calcium (CAC) score as a predictive tool?

What challenges are there in motivating individuals for early CVD interventions?

How does the lack of critical thinking hinder medical advancement once a consensus is reached?

PSK9 inhibitors and familial hypercholesterolemia: differing interpretations of the science

How do we define risk and uncertainty in medical guidelines?

Making clinical decisions in the face of uncertainty

How does the emphasis on consensus and unanimity weaken science and medicine?

What factors are holding back the advancement of apoB in CVD risk assessment?

What are the advantages of a 30-year risk assessment and early intervention?

Shownotes Transcript

#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk 02:02:13 Share

The Peter Attia Drive

Chapters

Why is the current 10-year risk assessment of CVD problematic for prevention?

What are the basics of cholesterol, apoB, and plasma lipoproteins?

How does particle cholesterol concentration impact CVD compared to the number of particles?

What are the limitations of standard blood panels in assessing CVD risk?

Remnant type III hyperlipoproteinemia—high cholesterol, low Apo B, high triglyceride

Can apoB effectively estimate the risk of CVD?

How is Mendelian randomization supporting ApoB as a superior risk metric?

What role does hypertension play in CVD risk?

What factors influence the decision to start preventative intervention for CVD?

How effective is the coronary artery calcium (CAC) score as a predictive tool?

What challenges are there in motivating individuals for early CVD interventions?

How does the lack of critical thinking hinder medical advancement once a consensus is reached?

PSK9 inhibitors and familial hypercholesterolemia: differing interpretations of the science

How do we define risk and uncertainty in medical guidelines?

Making clinical decisions in the face of uncertainty

How does the emphasis on consensus and unanimity weaken science and medicine?

What factors are holding back the advancement of apoB in CVD risk assessment?

What are the advantages of a 30-year risk assessment and early intervention?

Shownotes Transcript

#185 - Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk